Repligen said to have rejected $14 billion takeover offer from Catalent, reports StreetInsider
Betaville notes rivals at StreetInsider have picked up on the Repligen Corporation takeover rumour that has been doing the rounds in the last few days.
According to StreetInsider, Catalent - a US-listed biopharmaceutical company - has been circling Repligen, which makes materials used in the manufacture of biological drugs...
Register
Register for free to see rest of this article and all public articles from Betaville
Login / RegisterDate: Thursday, 11 August 2022, 9:17 pm